MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Loss of membrane MHC class I protein expression in most of tumor cells in advanced melanomas predicts primary resistance to anti–CTLA-4, but not anti-PD1, treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In another study, MHC I downregulation via transcriptional repression was associated with primary resistance to anti-CTLA-4 therapy but not to anti-PD-1 therapy, and the response to anti-PD-1 was more dependent on MHC II expression linked to an IFN-γ-regulated module of genes (97).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [97]
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationSalmon provides fast and bias-aware quantification of transcript expression
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A., & Kingsford, C. (2017) · Nature Methods · doi:10.1038/nmeth.4197 · Cited by 12,700
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Cited by
Items 301–400 of 623
Pourmaleki, M., Young, J. H., Socci, N. D., Chiang, S., Edelweiss, M., Li, Y., Zhang, M., Roshal, L., Dennis, S., BUSAM, K. J., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27247 · Cited by 21
Haugh, A. M., Salama, A. K. S., & Johnson, D. B. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.09.005 · Cited by 20
Hargadon, K. M. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20608 · Cited by 20
Blair, T. C., Alice, A. F., Zebertavage, L., Crittenden, M. R., & Gough, M. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.653625 · Cited by 20
Bestion, E., Rachid, M., Tijeras‐Raballand, A., Roth, G. S., Decaens, T., Ansaldi, C., Mezouar, S., Raymond, É., & Halfon, P. (2023) · Targeted Oncology · doi:10.1007/s11523-023-01019-8 · Cited by 20
Iwasaki, A., Shinozaki‐Ushiku, A., Kunita, A., Yamazawa, S., Sato, Y., Yamashita, H., Fukayama, M., Seto, Y., & Ushiku, T. (2021) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001779 · Cited by 20
Heng, Y., Zhu, X., Wu, Q., Lin, H., Ding, X., Tao, L., & Lu, L. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101678 · Cited by 20
Lost in the crowd: identifying targetable MHC class I neoepitopes for cancer immunotherapy
Wilson, E., & Anderson, K. S. (2018) · Expert Review of Proteomics · doi:10.1080/14789450.2018.1545578 · Cited by 20
Luo, Z., Huang, X., Xu, X., Wei, K., Zheng, Y., Gong, K., & Li, W. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0382 · Cited by 19
Immunotherapy for diffuse gastric cancer: challenges and new avenues
Zhou, Y., & Li, J. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01052-y · Cited by 19
Gao, L., Zhang, A., Yang, F., & Du, W. (2022) · Vaccines · doi:10.3390/vaccines10081272 · Cited by 19
Stephan-Falkenau, S., Streubel, A., Mairinger, T., Blum, T.-G., Kollmeier, J., Mairinger, F. D., Bauer, T. T., Pfannschmidt, J., Hollmann, M., & Wessolly, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310558 · Cited by 19
Single-cell analysis identifies PLK1 as a driver of immunosuppressive tumor microenvironment in LUAD
Kong, Y., Li, C., Liu, J., Zhang, M., Allison, D. B., Hassan, F., He, D., Wang, X., Mao, F., Zhang, Q., et al. (2024) · PLoS Genetics · doi:10.1371/journal.pgen.1011309 · Cited by 19
Massa, D., Tosi, A., Rosato, A., Guarneri, V., & Dieci, M. V. (2022) · Cancers · doi:10.3390/cancers14194885 · Cited by 18
Tumor cells fail to present MHC-II–restricted epitopes derived from oncogenes to CD4+ T cells
Brightman, S. E., Naradikian, M. S., Thota, R. R., Becker, A., Montero, L., Bahmanof, M., Premlal, A. L. R., Greenbaum, J., Peters, B., Cohen, E. E. W., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.165570 · Cited by 18
Kim, K., Alam, S. M., Kuo, F., Chen, Z., Yip, W., Katims, A., Chu, C. E., Lenis, A. T., Hu, W., Ozcan, G. G., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.10.024 · Cited by 18
Lanuza, P. M., Alonso, M. H., Hidalgo, S., Uranga-Murillo, I., García‐Mulero, S., Arnau, R., Santos, C., Sanjuán, X., Santiago, L., Comas, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.890836 · Cited by 18
Wang, X., Li, S., Yan, S., Shan, Y., Wang, X., Jingbo, Z., Wang, Y., Shan, F., Griffin, N., & Sun, X. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109125 · Cited by 17
Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy
Nagayama, S., Low, S., Kiyotani, K., & Nakamura, Y. (2021) · Cancers · doi:10.3390/cancers13194803 · Cited by 17
Understanding genetic determinants of resistance to immune checkpoint blockers
Aspeslagh, S., Chabanon, R. M., Champiat, S., & Postel-Vinay, S. C. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.020 · Cited by 17
Development and Validation of Novel Prognostic Models for Immune-Related Genes in Osteosarcoma
Li, J., Su, L., Xiao, X., Wu, F., Du, G., Guo, X., Kong, F., Yao, J., & Zhu, H. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.828886 · Cited by 17
Ladányi, A., Papp, E., Mohos, A., Balatoni, T., Liszkay, G., Oláh, J., Varga, A., Lengyel, Z., Emri, G., & Ferrone, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000209 · Cited by 17
Tran, M. A., Cho, B. A., Izadmehr, S., Yoo, S., Youssef, D., Anker, J. F., Farkas, A. M., Figueiredo, I., Lee, K., Ananthanarayanan, A., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1774 · Cited by 17
Rasmussen, M., Durhuus, J. A., Nilbert, M. C., Andersen, O., & Therkildsen, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010329 · Cited by 16
Schoemmel, M., Loeser, H., Kraemer, M., Wagener‐Ryczek, S., Hillmer, A. M., Bruns, C. J., Thelen, M., Schröder, W., Zander, T., Lechner, A., et al. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02556-2 · Cited by 16
Tarantino, G., Ricker, C. A., Wang, A., Ge, W. H., Aprati, T. J., Huang, A. Y., Madha, S., Chen, J., Shi, Y., Glettig, M., et al. (2024) · Science Advances · doi:10.1126/sciadv.adp4670 · Cited by 16
Self-citationAyub, A., Hasan, M. K., Mahmud, Z., Hossain, M. S., & Kabir, Y. (2024) · Medical Oncology · doi:10.1007/s12032-024-02417-2 · Cited by 16
Epigenome-Driven Strategies for Personalized Cancer Immunotherapy
Rocha, G. I. Y., Gomes, J. E. M., Leite, M. L., da Cunha, N. B., & Costa, F. F. (2023) · Cancer Management and Research · doi:10.2147/cmar.s272031 · Cited by 16
Stupia, S., Heeke, C., Brüggemann, A., Zaremba, A., Thier, B., Kretz, J., Sucker, A., Philip, M., Zelinskyy, G., Ferrone, S., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0099 · Cited by 16
CD4+ cytotoxic T cells: an emerging effector arm of anti-tumor immunity
Jeong, S., Jang, N., Kim, M., & Choi, I. (2023) · BMB Reports · doi:10.5483/bmbrep.2023-0014 · Cited by 16
Peng, S., Chen, L., Deng, R., Li, H., Liu, X., Zheng, D., Wu, C., Liu, C., Sun, Z., & Zhang, X. (2021) · Nanoscale · doi:10.1039/d1nr00830g · Cited by 16
HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab
Ladányi, A., Hegyi, B., Balatoni, T., Liszkay, G., Rohregger, R., Waldnig, C., Dudás, J., & Ferrone, S. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610297 · Cited by 16
Ovarian cancer ascites proteomic profile reflects metabolic changes during disease progression
Almeida-Nunes, D. L., Nunes, M., Osório, H., Ferreira, V., Lobo, C., Monteiro, P., Abreu, M. H., Bartosch, C., Silvestre, R., Dinis‐Oliveira, R. J., et al. (2024) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2024.101755 · Cited by 16
Detection of clinically relevant immune checkpoint markers by multicolor flow cytometry
Cunningham, R., Holland, M., McWilliams, E. M., Hodi, F. S., & Severgnini, M. (2019) · Journal of Biological Methods · doi:10.14440/jbm.2019.283 · Cited by 16
Self-citationPoletto, S., Paruzzo, L., Nepote, A., Caravelli, D., Sangiolo, D., & Carnevale‐Schianca, F. (2023) · Cancers · doi:10.3390/cancers16010101 · Cited by 15
Zou, Y., & Yaguchi, T. (2023) · Experimental Dermatology · doi:10.1111/exd.14750 · Cited by 15
Feng, H.-R., Shen, X., Zhu, X., Zhong, W.-T., Zhu, D.-X., Zhao, J., Chen, Y.-J., Shen, F., Liu, K., & Liang, L. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217062 · Cited by 15
STUB1 is an intracellular checkpoint for interferon gamma sensing
Ng, S., Lim, S., Sim, A. C. N., Mangadu, R., Lau, A., Zhang, C., Martinez, S. B., Chandramohan, A., Lim, U.-M., Ho, S. S. W., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-18404-4 · Cited by 15
Long, F., Ma, H., Hao, Y., Tian, L., Li, Y., Li, B., Chen, J., Tang, Y., Li, J., Deng, L., et al. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.05.013 · Cited by 15
Cao, J., Tu, D., Zhou, J., Jiang, G., Jin, S., Su, B., Tang, H., Tang, Y., Wang, A.-Q., Wang, Q., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997265 · Cited by 15
Assessment of cancer cell‐expressed HLA class I molecules and their immunopathological implications
Kubo, T., Asano, S., Sasaki, K., Murata, K., Kanaseki, T., Tsukahara, T., Hirohashi, Y., & Torigoe, T. (2024) · HLA · doi:10.1111/tan.15472 · Cited by 15
Marijt, K. A., Griffioen, L., Blijleven, L., van der Burg, S. H., & van Hall, T. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02984-7 · Cited by 15
Ji, Z., Ren, W., Yang, S., Wang, D., Jiang, Z., Lin, C., Ye, J., & Tian, W.-T. (2022) · PubMed Central · Cited by 15
Immune‐check blocking combination multiple cytokines shown curative potential in mice tumor model
Su, H., Geng, H., Cai, L., Xu, M., Xing, W., Long, W., Liu, B., Li, Y., & Liu, B. (2023) · Cancer Medicine · doi:10.1002/cam4.6053 · Cited by 14
Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors
Pezeshki, P. S., Sharif, P. M., & Rezaei, N. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1929919 · Cited by 14
Liu, R., Dollinger, E., & Nie, Q. H. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.806457 · Cited by 14
Marletta, S., Girolami, I., Munari, E., Pantanowitz, L., Bernasconi, R., Torresani, E., Brunelli, M., & Eccher, A. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2020.1869732 · Cited by 14
Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma
Horowitch, B., Lee, D. Y., Ding, M., Martínez-Morilla, S., Aung, T. N., Ouerghi, F., Wang, X., Wei, W., Damsky, W., Sznol, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0215 · Cited by 15
Yan, S., Zhang, X., Lin, Q., Du, M., Li, Y., He, S., Chen, J., Li, X., Bei, J., Chen, S., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03789-0 · Cited by 14
High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma
Silk, A. W., Kaufman, H. L., Curti, B. D., Mehnert, J. M., Margolin, K. A., McDermott, D. F., Clark, J. I., Newman, J. H., Bommareddy, P. K., Denzin, L. K., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01483 · Cited by 14
Wang, B., Liu, Y., Xiong, F., & Wang, C. (2024) · Pharmaceuticals · doi:10.3390/ph17060678 · Cited by 14
Biological mechanism and immune response of MHC-II expression in tumor cells
Zhou, M., Pan, S., Zhang, Y., Hu, C., & Xu, Z. (2025) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2025.0248 · Cited by 14
Szabó, I. L., Emri, G., Ladányi, A., & Tímár, J. (2025) · Cancers · doi:10.3390/cancers17091422 · Cited by 13
Dirks, I., Keyaerts, M., Dirven, I., Neyns, B., & Vandemeulebroucke, J. (2023) · Cancers · doi:10.3390/cancers15164083 · Cited by 12
Huang, Z.-J., Xu, J., Wang, Y., Fu, Z., Zhang, Y., Zhao, Q., Zhang, R., Hu, X., Cheng, X., & Hu, C. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105057 · Cited by 12
The genetic and epigenetic basis of distinct melanoma types
Oba, J., & Woodman, S. E. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15957 · Cited by 12
Elucidating DNA Damage-Dependent Immune System Activation
Deligianni, E., Papanikolaou, C., Terpos, E., & Souliotis, V. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125849 · Cited by 12
Deng, H., Chen, Y., Wang, J., & An, R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274897 · Cited by 12
Sakai, S. A., Saeki, K., Chi, S., Hamaya, Y., Du, J., Nakamura, M., Hojo, H., Kojima, T., Nakamura, Y., Bando, H., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0610 · Cited by 12
Sarcoma Common MHC-I Haplotype Restricts Tumor-Specific CD8+ T Cell Response
Mosca, L., Angelis, A. D., Ronchi, A., Chiara, A. D., Fazioli, F., Ruosi, C., Altucci, L., Conte, M., & de Nigris, F. (2022) · Cancers · doi:10.3390/cancers14143414 · Cited by 12
Qu, J., Guan, H., Zheng, Q., & Sun, F. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.129584 · Cited by 12
Distinct Molecular Mechanisms of Altered HLA Class II Expression in Malignant Melanoma
Meyer, S., Handke, D., Mueller, A., Biehl, K., Kreuz, M., Bukur, J., Koehl, U., Lazaridou, M., Berneburg, M., Steven, A., et al. (2021) · Cancers · doi:10.3390/cancers13153907 · Cited by 12
Wang, Y., Jasinski‐Bergner, S., Wickenhauser, C., & Seliger, B. (2022) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000389 · Cited by 12
Rodriguez, G. M., Yakubovich, E., Murshed, H., Maranda, V., Galpin, K. J. C., Cudmore, A. O., Hanna, A. M. R., Macdonald, E. A., Ramesh, S., Garson, K., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1295208 · Cited by 12
The human leukocyte antigen as a candidate tumor suppressor
Pujadas, E., & Cordon‐Cardo, C. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.02.005 · Cited by 12
Hashimoto, A., Handa, H., Hata, S., & Hashimoto, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1005566 · Cited by 11
Garg†, S. K., Welsh, E. A., Fang, B., Hernandez, Y., Rose, T. A., Gray, J. E., Koomen, J. M., Berglund, A., Mulé, J. J., & Markowitz, J. (2020) · Cancers · doi:10.3390/cancers12123515 · Cited by 12
Ju, W., Cai, H., Zheng, W., Li, D., Zhang, W., Yang, X.-H., & Yan, Z. (2024) · Oncology Letters · doi:10.3892/ol.2024.14215 · Cited by 11
Robbins, Y. L., Friedman, J., Redman, J. M., Sievers, C. M., Lassoued, W., Gulley, J. L., & Allen, C. T. (2023) · Oral Oncology · doi:10.1016/j.oraloncology.2023.106309 · Cited by 11
Biomarker Predictors for Immunotherapy Benefit in Breast: Beyond PD-L1
James, J. L., & Balko, J. M. (2019) · Current Breast Cancer Reports · doi:10.1007/s12609-019-00331-5 · Cited by 11
Predictive Biomarkers: Progress on the Road to Personalized Cancer Immunotherapy
Emens, L. A. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab068 · Cited by 11
Tackling HLA Deficiencies Head on with Oncolytic Viruses
Fisher, K. D., Hazini, A., & Seymour, L. W. (2021) · Cancers · doi:10.3390/cancers13040719 · Cited by 11
Shembrey, C., Behrenbruch, C., Loveday, B. P. T., Heriot, A. G., Foroutan, M., & Hollande, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1011247 · Cited by 11
He, L.-N., Liu, Y.-J., Jiang, J., Wang, D.-Y., Li, Y., Zeng, S.-J., Guo, Z., Yao, P.-Y., Lin, Z.-C., Lv, S., et al. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01507-9 · Cited by 11
van der Westhuizen, A., Lyle, M. K., Graves, M. C., Zhu, X., Wong, J. W. H., Cornall, K., Ren, S. P., Pugliese, L., Levy, R., Majid, A., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0128 · Cited by 11
Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma
Pourmaleki, M., Jones, C. J., Ariyan, C. E., Zeng, Z., Pirun, M., Navarrete, D. A., Li, Y., Zhang, M., Nandakumar, S., Campos, C., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-1083 · Cited by 11
Li, L., Wang, X., Jiang, M., Li, L., Wang, D., & Li, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117420 · Cited by 11
Yamashita, S., Abé, H., Yamashita, H., Yagi, K., Seto, Y., & Ushiku, T. (2023) · Histopathology · doi:10.1111/his.14924 · Cited by 11
Xu, Y., Shen, H., Shang, D., & Zhu, C. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1665239 · Cited by 10
Ye, D., Zhou, S. Y., Dai, X., Xu, H., Tang, Q., Huang, H., & Bi, F. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189161 · Cited by 10
Zhao, H., Tian, H., Nuerbieke, T., Ma, K., Li, W., Niu, X., Li, J., Ashby, C. R., Chen, Z., Zhou, T., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218690 · Cited by 10
Shi, M., Chen, Y., & Ji, D. (2022) · Future Oncology · doi:10.2217/fon-2022-0061 · Cited by 10
Mints, M., Sample, R. A., Parikh, A. S., Zaretsky, J. M., Qi, Z., Law, T. E., Wang, F., Barrett, T. F., Mullins, R. D. Z., Reeb, A. N., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102715 · Cited by 10
Karime, C., Wang, J., Woodhead, G. J., Mody, K., Hennemeyer, C. T., Borad, M. J., Mahadevan, D., Chandana, S. R., & Babiker, H. M. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2019706 · Cited by 10
The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma
Ye, T., Zhang, J., Liu, X.-Y., Zhou, Y., Yuan, S., Yang, M., Xie, W., Gao, C., Chen, Y., Huang, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.785526 · Cited by 10
Adams, A. C., Borden, E. S., Macy, A. M., Thomson, N., Cui, H., Gimbel, M. I., Wilson, M. A., Buetow, K. H., Roe, D. J., DiCaudo, D. J., et al. (2022) · Cancers · doi:10.3390/cancers14092200 · Cited by 10
TRIM22 negatively regulates MHC-II expression
Inoue, A., Watanabe, M., Kondo, T., Hirano, S., & Hatakeyama, S. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119318 · Cited by 10
Current Status and Molecular Mechanisms of Resistance to Immunotherapy in Oral Malignant Melanoma
Usta, S. Z., Uchihashi, T., Kodama, S., Kurioka, K., Inubushi, T., Shimooka, T., Sugauchi, A., Seki, S., & Tanaka, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417282 · Cited by 9
Immune Regulation and Immune Therapy in Melanoma: Review with Emphasis on CD155 Signalling
Wu, L., Park, S.-H., Jakobsson, H., Shackleton, M. J., & Möller, A. (2024) · Cancers · doi:10.3390/cancers16111950 · Cited by 10
Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas
Verver, D., Poirier-Colame, V., Tomasic, G., Cherif-Rebai, K., Grünhagen, D. J., Verhoef, C. K., Suciu, S., Robert, C., Zitvogel, L., & Eggermont, A. M. M. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1660121 · Cited by 9
Ikeda, H., Nagasaki, J., Shimizu, D., Katsuya, Y., Horinouchi, H., Hosomi, Y., Tanji, E., Iwata, T., Itami, M., Kawazu, M., et al. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100573 · Cited by 9
Yang, X., Wu, J., Fan, L., Chen, B., Zhang, S., & Zheng, W. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s457570 · Cited by 9
Giguelay, A., Maschmeyer, P., Müller‐Jensen, L., Schinke, C., Maierhof, S. K., Nambiar, N., Meyer, M., Huehnchen, P., Boehmerle, W., Endres, M., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012350 · Cited by 9
Anichini, A., Caruso, F. P., Lagano, V., Noviello, T., Tufano, R., Nicolini, G., Molla, A., Bersani, I., Sgambelluri, F., Covre, A., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03474-9 · Cited by 9
Monoclonal antibody pharmacogenomics in cancer treatment
Yagishita, S., & Hamada, A. (2019) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2019.026 · Cited by 9
Distinctive gene expression patterns in pregnancy-associated breast cancer
Wang, D., Peng, H., Hu, Y., Piao, X., Gao, D., & Sha, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.850195 · Cited by 9
Yang, C., Xu, Y., Lin, Z., Zhang, A., Li, X., Ye, Z., Zhang, Q., Hu, H., Ren, G., Cheng, P., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101261 · Cited by 9
Efficacy of Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Narrative Review
Perdikis-Prati, S., Sheikh, S., Bouroumeau, A., & Lang, N. (2023) · Biomedicines · doi:10.3390/biomedicines11061720 · Cited by 8
Immunotherapy Combinations for the Treatment of Patients with Solid Tumors
Bluthgen, M. V., Basté, N., & Recondo, G. (2020) · Future Oncology · doi:10.2217/fon-2020-0303 · Cited by 8
Sharif, P. M., Khoshbin, A. P., Nasrollahzadeh, E., Keshavarz‐Fathi, M., & Rezaei, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818006-8.00003-7 · Cited by 8
Metadata
- Authors
- Rodig, S. J., Gusenleitner, D., Jackson, D. G., Gjini, E., Giobbie-Hurder, A., Jin, C., Chang, H., Lovitch, S. B., Horak, C., Weber, J. S., Weirather, J. L., Wolchok, J. D., Postow, M. A., Pavlick, A. C., Chesney, J., & Hodi, F. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Bristol-Myers Squibb (United States) (US)
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- NYU Langone Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Louisville (US)
- Corresponding author
- Rodig, Scott J.
- Hodi, F. Stephen
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-07-18
- Volume
- 10
- Issue
- 450
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2883970691
- Cited by
- 579
- References
- 59
- Citations by year
- 2026: 38 · 2025: 48 · 2024: 75 · 2023: 101 · 2022: 94 · 2021: 79 · 2020: 76 · 2019: 55 · 2018: 12
- FWCI
- 20.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Funded by Bristol-Myers Squibb (N/A)
- NIH/NCI Cancer Center (P30 CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- metastatic melanoma, MHC class I expression, MHC class II expression, CTLA-4 blockade, anti-PD-1 therapy, immune checkpoint inhibitors, interferon-gamma, innate immunity, tumor antigen presentation, antitumor immunity, predictive biomarkers
- MeSH terms
- HLA Antigens, Humans, Immunity, Innate, Immunotherapy, Melanoma, Transcription, Genetic, Gene Expression Regulation, Neoplastic, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.